A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity

Current Medicinal Chemistry

Volumn 21, Issue 23, 2014, Pages 2642-2664

  Rajak, H ^a   Singh, A ^a   Raghuwanshi, K ^a   Kumar, R ^a   Dewangan, P K ^a   Veerasamy, R ^b   Sharma, P C ^c   Dixit, A ^d   Mishra, P ^e  

^a GURU GHASIDAS UNIVERSITY   (India)

^b AIMST UNIVERSITY   (Malaysia)

^c KURUKSHETRA UNIVERSITY   (India)

^d INSTITUTE OF LIFE SCIENCES   (India)

^e GLA UNIVERSITY   (India)

Author keywords

Anticancer agents; Belinostat; Givinostat; Histone; Histone deacetylase inhibitors; Hydroxamic acid; Panobinostat; Vorinostat

Indexed keywords

ALIPHATIC COMPOUND; ALKYL GROUP; AROMATIC COMPOUND; BENZENE DERIVATIVE; HETEROCYCLIC COMPOUND; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; ZINC; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CHEMICAL BINDING; CHEMICAL LABELING; CHEMICAL MODIFICATION; CHEMICAL PARAMETERS; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MEDICINAL CHEMISTRY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903723555     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990191     Document Type: Article

References (124)

1. Venugopal, B.; Evans, T.R.J. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem., 2011, 18, 1658-1671.
2. Acharya, M.L.; Sparreboom, A.; Venitz, J.; Figg, W.D. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol. Pharmacol., 2005, 68, 917-932.
3. Marks, P.A.; Miller, T.; Richon, V.M. Histone deacetylases. Curr. Opin. Pharmacol., 2003, 3, 344-351.
4. Rajak, H.; Singh, A.; Dewangan, P.K.; Patel, V.; Jain, D.K.; Tiwari, S.K.; Veerasamy, R.; Sharma, P.C. Peptide based macrocycles: Selective histone deacetylase inhibitors with antiproliferative activity. Curr. Med. Chem., 2013, In press, PMID: 23409715.
5. Ropero, S.; Esteller, M. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol., 2007, 1, 19-25.
6. Martinez-Iglesias, O.; Ruiz-Llorente, L.; Sanchez-Martinez, R.; Garcia, L.; Zambrano, A.; Aranda, A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol, 2008, 10, 395-398.
7. Marks, P.A.; Xu, W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem., 2009, 107, 600-608.
8. Monneret, C. Histone deacetylase inhibitors. Eur. J. Med. Chem., 2005, 40, 1-13.
9. Hess-Stumpp, H. Histone deacetylase inhibitors and cancer, from cell biology to the clinic. Eur. J. Cell Biol., 2005, 84, 109-121.
10. Finnin, M.S.; Donigian, J.R.; Cohen, A.; Richon, V.M.; Rifkind, R.A.; Marks, P.A.; Breslow, R.; Pavletich, N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 1999, 401, 188-193.
11. Miller, T.A.; Witter, D.J.; Belvedere, S.J. Histone deacetylase inhibitors. J. Med. Chem., 2003, 46, 5097-5116.
12. Prebet, T.; Vey, N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin. Investig. Drugs, 2011, 20, 287-295.
13. Wang, H.; Dymock, B.W. New patented histone deacetylase Inhibitors. Expert Opin. Ther. Patents, 2009, 19, 1727-1757.
14. Zhang, L.; Fang, H.; Xu, W. Strategies in developing promising histone deacetylase inhibitors. Med. Res. Rev., 2010, 30, 585-602.
15. Balasubramanian, S.; Verner, E.; Buggy, J.J. Isoform specific histone deacetylase inhibitors: The next step. Cancer Lett., 2009, 280, 211-221.
16. Dokmanovic, M.; Clarke, C.; Marks, P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res., 2007, 5, 981-989.
17. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology, implications for disease and therapy. Nat. Rev. Genet., 2009, 10, 32-42.
18. Ramalingam, S.S.; Belani, C.P.; Ruel, C.; Frankel, P.; Gitlitz, B.; koczywas, M.; Espinoza-Delgado, I.; Gandara, D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitors, for second line therapy of advanced malignant pleural mesothelioma. J. Thorac. Oncol., 2009, 4, 97-101.
19. Golay, J.; Cuppinni, L.; Leoni, F.; Mico, C.; Barbui, V.; Domenghini, M.; Lombardi, L.; Neri, A.; Barbui, A.M.; Salvi, A.; Pozzi, P.; Porro, G.; Pagani, P.; Fossati, G.; Mascagni, P.; Introna, M.; Rambaldi, A. The histone deacetylase inhibitor ITF2357 has antileukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007, 21, 1892-1900.
20. Kramer, O.H.; Gottlicher, M.; Heinzel, T. Histone deacetylase as a therapeutic target. Trends in Endocrin. Metabol. 2001, 12, 294-300.
21. Ma, X.; Ezzeldin, H.H.; Diasion, R.B. Histone deacetylase inhibitors, current status and overview of recent clinical trials. Drugs, 2009, 69, 1911-1934.
22. Marks, P.A. Histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs, 2010, 19, 1049-1066.
23. Tan, J.; Cang, S.; Ma, Y.; Petrillo, R.L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol., 2010, 3, 1-13.
24. Takai, N.; Kira, N.; Ishii, T.; Nishida, M.; Nasu, K.; Narahara, H. Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Asian Pacific J. Cancer Prev., 2011, 12, 575-580.
25. Andrianov, V.; Gailite, V.; Lola, D.; Loza, E.; Semenikhina, V.; Kalvinsh, I.; Finn, P.; Petersen, K.D.; Ritchie, J.W.A.; Khan, N.; Tumber, A.; Collins, L.S.; Vadlamudi, S.M.; Bjorkling, F.; Sehested, M. Eur. J. Med. Chem. 2009, 44, 1067-1085.
26. Henkes, L.M.; Haus, P.; Jager, F.; Ludwig, J.; Meyer-Almes, F.J. Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N- hydroxy-octanediamides as inhibitors of human histone deacetylases. Bioorg. Med. Chem., 2012, 20, 985-995.
27. Vaidya, A.S.; Neelarapu, R.; Madriaga, A.; Bai, H.; Mendonca, E.; Abdelkarim, H.; Van Breemen, R.B.; Blond, S.Y.; Petukhov, P.A. Novel histone deacetylase 8 ligands without a zinc chelating group: Exploring an 'upside-down' binding pose. Bioorg. Med. Chem. Lett., 2012, 22, 6621-6627.
28. Kozikowski, A.P.; Chen, Y.; Gaysin, A.; Chen, B.; D'Annibale, M.A.; Suto, C.M.; Langley, B.C. Functional differences in epigenetic modulators superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J. Med. Chem., 2007, 50, 3054-3061.
29. Chen, Y.; Sanchez, M.L.; Savoy, D.N.; Billadeau, D.D.; Dow, G.S.; Kozikowski, A.P. A series of potent and selective.; triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and plasmodium falciparum. J. Med. Chem., 2008, 51, 3437-3448.
30. He, R.; Chen, Y.; Chen, Y.; Ougolkov, A.V.; Zhang, J.S.; Savoy, D.N.; Billadeau, D.D.; Kozikowski, A.P. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents. J. Med. Chem., 2010, 53, 1347-1356.
31. Oanh, D.T.K.; Hai, H.V.; Park, S.H.; Kim, H.J.; Han, B.W.; Kim, H.S.; Hong, J.T.; Han, S.B.; Hue, V.T.M.; Nam, N.H. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Bioorg. Med. Chem. Lett., 2011, 21, 7509-7512.
32. Dai, Y.; Guo, Y.; Guo, J.; Pease, L.J.; Li, J.; Marcotte, P.A.; Glaser, KB.; Tapang, P.; Albert, D.H.; Richardson, P.L.; Davidsen, S.K.; Michaelides, M.R. Indole Amide Hydroxamic Acids as Potent Inhibitors of Histone Deacetylases. Bioorg. Med. Chem. Lett., 2003, 13, 1897-1901.
33. Giannini, G.; Marzi, M.; Marzo, M.D.; Battistuzzi, G.; Pezzi, R.; Brunetti, T.; Cabri, W.; Vesci, L.; Pisano, C. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 2840-2843.
34. Tang, W.; Luo, G.; EF, Bradner, J.E.; Schreiber, S.L. Discovery of histone deacetylase 8 selective inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 2601-2605.
35. Salisbury, C.M.; Cravatt, B.F. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J. Am. Chem. Soc., 2008, 130, 2184-2194.
36. Kozikowski, A.P.; Tapadar, S.; Luchini, D.N.; Kim, K.H.; Billadeau, D.D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation.; a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem., 2008, 51, 4370-4373.
37. He, B.; Velaparthi, S.; Pieffet, G.; Pennington, C.; Mahesh, A.; Holzle, DL.; Brunsteiner, M.; Breemen, R.; Blond, S.Y.; Petukhov, P.A. Binding ensemble profiling with photoaffinity labeling (beprofl) approach.; mapping the binding poses of hdac8 inhibitors. J. Med. Chem., 2009, 52, 7003-7013.
38. Neelarapu, R.; Holzle, D.L.; Velaparthi, S.; Bai, H.; Brunsteiner, M.; Blond, S.Y.; Petukhov, P.A. Design.; synthesis.; docking.; and biological evaluation of novel diazide-containing isoxazole-and pyrazole-based histone deacetylase probes. J. Med. Chem., 2011, 54, 4350-4364.
39. Ommeslaeghe, K.V.; Elaut, G.; Brecx, V.; Papeleu, P.; Iterbeke, K.; Geerlings, P.; Tourwe, D.; Rogiers, V. Amide Analogs of TSA.; Synthesis.; Binding Mode Analysis and HDAC Inhibition. Bioorg. Med. Chem. Lett., 2003, 13, 1861-1864.
40. Bouchain, G.; Delorme, D. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors.; synthesis and antiproliferative evaluation. Curr. Med. Chem., 2003, 10, 2359-2372.
41. Jung, M.; Brosch, G.; Kolle, D.; Scherf, H.; Gerhauser, C.; Loidl, P.J. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem., 1999, 42, 4669-4679.
42. Jung, M.; Hoffmann, K. Brosch, G. Loidl, P. Aalogues of trichostatin aand trapoxin B as histone deacetylase inhibitor. Bioorg. Med. Chem. Lett., 1997, 7, 1655-1658.
43. Remiszewski, S.W. The Discovery of NVP-LAQ824.; From Concept to Clinic. Curr. Med. Chem., 2003, 10, 2393-2402.
44. Remiszewski, S.W.; Sambucetti, L.C.; Atadja, P.; Bair, K.W.; Cornell, W.D.; Green, M.A.; Howell, K.L.; Jung, M.; Kwon, P.; Trogani, N.; Walker, H. Inhibitors of human histone deacetylase.; synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem., 2002, 45, 753-757.
45. Woo, S.H.; Frechette, S.; Khalil, E.A.; Bouchain, G.; Vaisburg, A.; Bernstein, N.; Moradei, O.; Leit, S.; Allan, M.; Fournel, M.; Trachy-Bourget, M.C.; Li, Z.; Besterman, J.M.; Delorme, D. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J. Med. Chem., 2002, 45, 2877-2885.
46. Zhang, Y.; Feng, J.; Jia, Y.; Xu, Y.; Liu, C.; Fang, H.; Xu, W. Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group. Eur. J. Med. Chem., 2011, 46, 5387-5397.
47. Curtin, M.L.; Garland, R.B.; Heyman, H.R.; Frey, R.R.; Michaelides, M.R.; Li, J.; Pease, LJ.; Glaser, KB.; Marcotte, PA.; Davidsen, SK. Succinimide Hydroxamic Acids as Potent Inhibitors of Histone Deacetylase (HDAC). Bioorg. Med. Chem. Lett., 2002, 12, 2919-2923.
48. Wittich, S.; Scherf, H.; Xie, C.; Brosch, G.; Loidl, P.; Gerha, C.; Jung, M. Structure activity relationships on phenylalaninecontaining inhibitors of histone deacetylase.; in vitro enzyme inhibition.; induction of differentiation.; and inhibition of proliferation in friend leukemic cells. J. Med. Chem., 2002, 45, 3296-3309.
49. Sundarapandian, T.; Shalini, J.; Sugunadevi, S.; Woo, L.K. Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. J. Mol. Graphics Modell., 2010, 29, 382-395.
50. Huang, W.J.; Chen, C.C.; Chao, S.W.; Yu, C.C.; Yui, Y.C.; Guh, J.H.; Lin, Y.C.; Kuo, C.I.; Yang, P.; Chang, C.I. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. Eur. J. Med. Chem., 2011, 46, 4042-4049.
51. Cai, X.; Zhai, H.X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin- 6-yloxy)-N-hydroxy-heptanamide (CUDc-101) as a potent multi-acting HDAC.; EGFR.; and HER2 inhibitor for the treatment of cancer. J. Med. Chem., 2010, 53, 2000-2009.
52. Belvedere, S.; Witter, DJ.; Yan, J.; Secrist, J.P.; Richona, V.; Millera, T.A. Aminosuberoyl hydroxamic acids (ASHAs).; A potent new class of HDAC inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 3969-3971.
53. Wang, H.; Lim, Z.Y.; Zhou, Y.; Ng, M.; Lu, T.; Lee, K.; Sangthongpitag, K.; Goh, K.C.; Wang, X.; Wub, X.; Khng, H.H.; Goh, S.K.; Ong, W.C.; Bonday, Z.; Sun, E.T. Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors, Synthesis, SAR, and in vivo antitumor activity. Bioorg. Med. Chem. Lett., 2010, 20, 3314-3321.
54. Marson, C.M.; Mahadevan, T.; Dines, J.; Sengmany, S.; Morrell, J.M.; Alao, J.P.; Joel, S.P.; Vigushin, D.M.; Coombes, R.C. Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett., 2007, 17, 136-141.
55. Glaser, KB.; Li, J.; Aakre, M.E.; Morgan, D.W.; Sheppard, G.; Stewart, K.D.; Pollock, J.; Lee, P.; O'Connor, C.Z.; Anderson, S.N.; Mussatto, D.J.; Wegner, C.W.; Moses, H.L. Transforming growth factor beta mimetics.; discovery of 7-4-(4-cyanophenyl)phenoxy.-heptanohydroxamic acid.; a biaryl hydroxamate inhibitor of histone deacetylase. Mol. Cancer Ther., 2002, 1, 759-768.
56. Marek, L.; Hamacher, A.; Hansen, F.K.; Kuna, K.; Gohlke, H.; Kassack, M.U.; Kurz, T. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J. Med. Chem., 2013, 56, 427-436.
57. Chen, P.C.; Patil, V.; Guerrant, W.; Green, P.; Oyelere, A.K. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorg. Med. Chem., 2008, 16, 4839-4853.
58. Dai, Y.; Guo, Y.; Curtin, M.L.; Li, J.; Pease, L.J.; Guo, J.; Marcotte, P.A.; Glaser, K.B.; Davidsen, S.K.; Michaelides, M.R. A Novel Series of Histone Deacetylase Inhibitors Incorporating Hetero Aromatic Ring Systems as Connection Units. Bioorg. Med. Chem. Lett., 2003, 13, 3817-3820.
59. Bigioni, M.; Ettorre, A.; Felicetti, P.; Mauro, S.; Rossi, C.; Maggi, C.A.; Marastoni, E.; Binaschi, M.; Parlani, M.; Fattori, D. Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e] azepin-6-ones as privileged structures. Bioorg. Med. Chem. Lett., 2012, 22, 5360-5362.
60. Grolla, A.A.; Podesta, V.; Chini, M.G.; Micco, SD.; Vallario, A.; Genazzani, A.A Canonico, P.L.; Bifulco, G.; Tron, G.C.; Sorba, G.; Pirali, T. Synthesis.; biological evaluation.; and molecular docking of ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases. J. Med. Chem., 2009, 52, 2776-2785.
61. Flipo, M.; Charton, J.; Hocine, A.; Dassonneville, S.; Deprez, B.; Poulain, R.D. Hydroxamates, relationships between structure and plasma stability. J. Med. Chem., 2009, 52, 6790-6802.
62. Choi, S.E.; Weerasinghe, S.V.W.; Pflum, M.K.H. The structural requirements of histone deacetylase inhibitors.; Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Bioorg. Med. Chem. Lett., 2011, 21, 6139-6142.
63. Chowdhury, N.; Dasgupta, S.; Singh, N.D.P. Photoinduced DNA cleavage by anthracene based hydroxamic acids. Bioorg. Med. Chem. Lett., 2012, 22, 4668-4671.
64. Luo, Y.; Liu, H.M.; Su, M.B.; Sheng, L.; Zhou, Y.B.; Li, J.; Lu, W. Synthesis and biological evaluation of piperamide analogs as HDAC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 4844-4846.
65. Marson, C.M.; Savy, P.; Rioja, A.S.; Mahadevan, T.; Mikol, C.; Veerupillai, A.; Nsubuga, E.; Chahwan, A.; Joel, S.P. Aromatic Sulfide Inhibitors of Histone Deacetylase Based on Arylsulfinyl-2.;4-hexadienoic Acid Hydroxyamides. J. Med. Chem., 2006, 49, 800-805.
66. Pabba, C.; Gregg, B.T.; Douglas, B.K.; Chen, Z.J.; Judkins, A. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 324-328.
67. Charrier, C.; Clarhaut, J.; Gesson, J.P.; Estiu, G.; Wiest, O.; Roche, J.; Bertrand, P. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. J. Med. Chem., 2009, 52, 3112-3115.
68. Arts, J.; Schepper, S.; Emelen, K.V. Histone deacetylase inhibitors from chromatin remodeling to experimental cancer therapeutics. Curr. Med. Chem., 2003, 10, 2343-2350.
69. Lavoie, R.; Bouchain, G.; Frechette, S.; Woo, S.H.; Khalil, E.A.; Leit, S.; Fournel, M.; Yan, P.T.; Trachy-Bourget, M.C.; Beaulieu, C.; Li, Z.; Besterman, J.; Delorme, D. Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2001, 11, 2847-2850.
70. Charles, M.M.; Serradji, N.; Rioja, A.S.; Gastaud, S.P.; Alao, J.P.; Coombesb, R.C.; Vigushinb, D.M. Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E.;4E)-5-arylpenta-2.;4-dienoic acid hydroxyamides. Bioorg. Med. Chem. Lett., 2004, 14, 2477-2481.
71. Vaisbure, A.; Bernstein, N.; Frechette, S.; Allan, M.; Khalil, E.A.; Leit, S.; Moradei, O.; Bouchain, G.; Wang, J.; Woo, S.H.; Fournel, M.; Yan, P.T.; Bourget, M.C.T.; Kalita, A.; Li, Z.; Macleod, A.R.; Bestermanab, J.M.; Delormea, D. (2-Amino-phenyl)-amides of !-substituted alkanoic acids as new histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 283-287.
72. Bouchain, G.; Leit, S.; Frechette, S.; Khalil, E.A.; Lavoie, R.; Moradei, O.; Woo, SH.; Fournel, M.; Yan, P.T.; Kalita, A.; Bourget, M.C.T.; Beaulieu, C.; Li, Z.; Robert, M.F.; MacLeod, A.R.; Besterman, J.M.; Delorme, D. Development of potential antitumor agents synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. J. Med. Chem., 2003, 46, 820-830.
73. Dallavalle, S.; Cincinelli, R.; Nannei, R.; Merlini, L.; Morini, G.; Penco, S.; Pisano, C.; Vesci, L.; Barbarino, M.; Zuco, V.; Cesare, M.D.; Zunino, F. Design.; synthesis and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur. J. Med. Chem., 2009, 44, 1900-1912.
74. Kim, D.K.; Lee, J.Y.; Kim, J.S.; Ryu, J.H.; Choi, J.Y.; Lee, J.W.; Im, G.J.; Kim, T.K.; Seo, J.W.; Park, H.J.; Yoo, J.; Park, J.H.; Kim, T.Y.; Bang, Y.J. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-n-hydroxy- 2-propenamides.; a new class of histone deacetylase inhibitors. J. Med. Chem., 2003, 46, 5745-5751.
75. Smil, D.V.; Manku, S.; Chantign,YA.; Leit, S.; Wahhab, A.; Yan, T.P.; Fournel, M.; Maroun, C.; Li, Z.; Lemieux, A.M.; Nicolescu, A.; Rahil, J.; Lefebvre, S.; Panetta, A.; Besterman, J.M.; Déziel, R. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 688-692.
76. Shultz, MD.; Cao, X.; Chen, C.H.; Cho, Y.S.; Davis, N.R.; Eckman, J.; Fan, J.; Fekete, A.; Firestone, B.; Flynn, J.; Green, J.; Growney, JD.; Holmqvist, M.; Hsu, M.; Jansson, D.; Jiang, L.; Kwon, P.; Liu, G.; Lombardo, F.; Lu, Q.; Majumdar, D.; Meta, C.; Perez, L.; Pu, M.; Ramsey, T.; Remiszewski, S.; Skolnik, S.; Traebert, M.; Urban, L.; Uttamsingh, V.; Wang, P.; Whitebread, S.; Whitehead, L.; Neale, Y.Y.; Yao, Y.M.; Zhou, L.; Atadja, P. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J. Med. Chem., 2011. 54, 4752-4772.
77. Chen, L.; Petrelli, R.; Gao, G.; Wilson, D.J.; McLean, G.T.; Jayaram, H.N.; Sham, Y.Y.; Pankiewicz, K.W. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorg. Med. Chem., 2010, 18, 5950-5964.
78. Curtin, M.; Glaser, K. Histone Deacetylase Inhibitors.; The Abbott Experience. Curr. Med. Chem., 2003, 10, 2373-2392.
79. Lu, Q.; Yang, Y.T.; Chen, C.S.; Davis, M.; Byrd, J.C.; Etherton, M.R.; Umar, A.; Chen, C.S. Zn2+-chelating motif-tethered shortchain fatty acids as a novel class of histone deacetylase inhibitors. J. Med. Chem., 2004, 47, 467-474.
80. Mai, A.; Massa, S.; Rotili, D.; Simeoni, S.; Ragno, R.; Botta, G.; Nebbioso, A.; Miceli, M.; Altucci, L.; Brosch, G. Synthesis and biological properties of novel.; uracil-containing histone deacetylase inhibitors. J. Med. Chem., 2006, 49, 6046-6056.
81. Mahboobi, S.; Sellmer, A.; Hocher, H.; Garhammer, C.; Pongratz, H.; Maier, T.; Ciossek, T.; Beckers, T. 2-Aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors. J. Med. Chem., 2007, 50, 4405-4418.
82. Cheng, X.C.; Wang, R.L.; Dong, Z.K.; Li, J.; Li, Y.Y.; Li, R.R. Design, synthesis and evaluation of novel metalloproteinase inhibitors based on l-tyrosine scaffold. Bioorg. Med. Chem., 2012, 20, 5738-5744.
83. Yoon, H.C.; Choi, E.; Park, JE.; Cho, M.; Seo, J.J.; Ohb, S.J.; Kang, S.J. Property based optimization of δ-lactam HDAC inhibitors for metabolic stability. Bioorg. Med. Chem. Lett., 2010, 20, 6808-6811.
84. Kim, H.M.; Ryu, D.K.; Choi, Y.; Park, B.W.; Lee, K.; Han, S.B.; Lee, CW.; Kang, M.R.; Kang, J.S.; Boovanahalli, S.K.; Park, S.K.; Han, J.W.; Chun, T.G.; Lee, H.Y.; Nam, K.Y.; Choi, E.H.; Han, G. Structure-activity relationship studies of a series of novel δ-lactambased histone deacetylase inhibitors. J. Med. Chem., 2007, 50, 2737-2741.
85. Kim, H.M.; Hong, S.H.; Kim, M.S.; Lee, C.W.; Kang, J.S.; Lee, K.; Park, S.K.; Han, J.W.; Lee, H.Y.; Choi, Y.; Kwon, H.J.; Hanb, G. Modification of cap group in δ-lactam-based histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 6234-6238.
86. Choi, E.; Lee, C.; Park, J.E.; Seo, J.J.; Cho, M.; Kang, J.S.; Kim, H.M. Structure and property based design.; synthesis and biological evaluation of δ-lactam based HDAC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 1218-1221.
87. Rossi, C.; Porcelloni, M., D'Andrea, P.; Fincham, CI.; Ettorre, A.; Mauro, S.; Squarcia, A.; Bigioni, M.; Parlani, M.; Nardelli, F.; Binaschi, M.; Maggi, C.A.; Fattori, D. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 2305-2308.
88. Chetan, B.; Bunha, M.; Jagrat, M.; Sinha, B.N.; Saiko, P.; Graser, G.; Szekeres, T.; Raman, G.; Rajendran, P.; Moorthy, D.; Basu, A.V. Design.; synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity. Bioorg. Med. Chem. Lett., 2010, 20, 3906-3910.
89. Rajak, H.; Agarawal, A.; Parmar, P.; Thakur, BS.; Veerasamy, R.; Sharma, C.P.; Kharya, M.D. 2.;5-Disubstituted-1.;3.;4-oxadiazoles/thiadiazole as surface recognition moiety.; Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 5735-5738.
90. Uesato, S.; Kitagawa, M.; Nagaoka, Y.; Maeda, T.; Kuwajima, H.; Yamori, T. Novel histone deacetylase inhibitors.; N-hydroxycarboxamides possessing a terminal bicyclic aryl group. Bioorg. Med. Chem. Lett., 2002, 12, 1347-1349.
91. Lee, C.;Choi, E.; Cho, M.; Lee, B.; Oh, S.J.; Park, S.K.; Lee, K.; Kim, H.M.; Han, G. Structure and property based design, synthesis and biological evaluation of δ-lactam based HDAC inhibitors: Part II. Bioorg. Med. Chem. Lett., 2012, 22, 4189-4192.
92. Conti, P.; Tamborini, L.; Pinto, A.; Sola, L.; Ettari, R.; Mercurio, C.; Micheli, C.D. Design and synthesis of novel isoxazole-based HDAC inhibitors. Eur. J. Med. Chem., 2010, 45, 4331-4338.
93. Tapadar, S.; He, R.; Luchini, D.N.; Billadeau, D.D.; Kozikowski, A.P. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group.; Effects on HDAC biology and antiproliferative activity. Bioorg. Med. Chem. Lett., 2009, 19, 3023-3026.
94. Hong Su.; Nebbioso A.; Carafa V.; Chen Y.; Yang B.; Altucci L.; You Q. Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents. Bioorg. Med. Chem., 2008, 16, 7992-8002.
95. Price, S.; Bordogna, W.; Bull, R.J.; Clark, D.E.; Crackett, P.H.; Dyke, H.J.; Gill, M.; Harris, N.V.; Gorski, J.; Lloyd, J.; Lockey, P.M.; Mullett, J.; Roach, A.G.; Roussel, F.; White, A.B. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 370-375.
96. Price, S.; Bordogn, W.; Braganza, R.; Bull, R.J.; Dyke, H.J.; Gardan, S.; Gill, M.; Harris, N.V.; Heald, R.A.; Heuvel, Mvd.; Lockey, P.M.; Lloyd, J.; Molina, A.G.; Roach, A.G.; Roussel, F.; Sutton, J.M.; White, A.B. Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2- hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 363-369.
97. Mai, A.; Massa, S.; Ragno, R.; Esposito, M.; Sbardella, G.; Nocca, G.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. Binding mode analysis of 3-(4-benzoyl-1-methyl-1h-2-pyrrolyl)-n-hydroxy-2-propenamide.; a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation.; growth inhibition.; and terminal cell differentiation. J. Med. Chem., 2002, 45, 1778-1784.
98. Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Ragno, R.; Bottoni, P.; Scatena, R.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy- 2-propenamides as a new class of synthetic histone deacetylase inhibitors 2 effect of pyrrole-C2 and/or-C4 substitutions on biological activity. J. Med. Chem., 2004, 47, 1098-1109.
99. Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G. Class II (IIa)-selective histone deacetylase inhibitors 1 synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem., 2005, 48, 3344-3353.
100. Ragno, R.; Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Bottoni, P.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-pyrrol- 2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors 3 discovery of novel lead compounds through structure-based drug design and docking studies. J. Med. Chem., 2004, 47, 1351-1359.
101. Massa, S.; Artico, M.; Corelli, F.; Mai, A.; Santo, RD.; Cortes, S.; Marongiu, ME.; Pani, A.; La Colla, P. Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogs of trichostatin A. J. Med. Chem., 1990, 33, 2845-2849.
102. Mai, A.; Massa, S.; Pezzi, R.; Rotili, D.; Loidl, P.; Brosch, G. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J. Med. Chem., 2003, 46, 4826-4829.
103. Hou, J.; Feng, C.; Li, Z.; Fang, Q.; Wang, H.; Gu, G.; Shi, Y.; Liu, P.; Xu, F.; Yin, Z.; Shen, J.; Wang, P. Structure-based optimization of click-based histone deacetylase inhibitors. Eur. J. Med. Chem., 2011, 46, 3190-3200.
104. Lai, M.J.; Huang, H.L.; Pan, S.L.; Liu, Y.M.; Peng, C.Y.; Lee, H.Y.; Yeh, T.K.; Huang, P.H.; Teng,C.M.; Chen, C.S.; Chuang, H.Y.; Liou, J.P. Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide) indoles as potent histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem., 2012, 55, 3777-3791.
105. Lee, S.; Shinji, C.; Ogura, K.; Shimizu, M.; Maeda, S.; Sato, M.; Yoshida, M.; Hashimotoa, Y.; Miyachia, H. Design.; synthesis.; and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 4895-4900.
106. Wang, H.; Yu, N.; Song, H.; Chen, D.; Zou, Y.; Deng, W.; Lye, PL.; Chang, J.; Ng, M.; Blanchard, S.; Sun, ET.; Sangthongpitag, K.; Wang, X.; Goh, K.C.; Wu, X.; Khng, H.H.; Fang, L.; Goh, S.K.; Ong, W.C.; Bonday, Z.; Stünkel, W.; Poulsen, A.; Entzeroth, M. N-Hydroxy-1.;2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors.; Design.; synthesis.; SAR studies.; and in vivo antitumor activity. Bioorg. Med. Chem. Lett., 2009, 19, 1403-1408.
107. Shinji, C.; Nakamura, T.; Maeda, S.; Yoshida, M.; Hashimotoa, Y.; Miyachia, H. Design and synthesis of phthalimide-type histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 4427-4431.
108. Zhang, Y.; Feng, J.; Liu, C.; Fang, H.; Xu, W. Design.; synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors. Bioorg. Med. Chem., 2011, 19, 4437-4444.
109. Donald, A.D.G.; Clark, V.L.; Patel, S.; Day, F.A.; Martin, G.; Rowlands, Wibata, J.; Stimson, L.; Hardcastle, A.; Eccles, S.A.; McNamara, D.; Needham, L.A.; Raynaud, F.I.; Aherne, W.; Moffat, D.F. Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases. Bioorg. Med. Chem. Lett., 2010, 20, 6657-6660.
110. Suzuki,T.; Ota, Y.; Ri, M.; Bando, M.; Gotoh, A.; Itoh, Y.; Tsumoto, H.; Tatum, P.R.; Mizukami, T.; Nakagawa,H.; Iida, S.; Ueda, R.; Shirahige, K.; Miyata, N. rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J. Med. Chem., 2012, 55, 9562-9575.
111. Wang, H.; Dymock, B.W. New patented histone deacetylase inhibitors. Expert Opin. Ther. Patents, 2009, 19, 1727-1757.
112. Varasi, M.; Thaler, F.; Abate, A.; Bigogno, C.; Boggio, R.; Carenzi, G.; Cataudella, T.; Zuffo, R.D.; Fulco, M.C.; Rozio, M.G.; Mai, A.; Dondio, G.; Minucci, S.; Mercurio, C. Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors. J. Med. Chem., 2011, 54, 3051-3064.
113. Glenn, M.P.; Kahnberg, P.; Boyle, G.M.; Hansford, K.A.; Hans, D.; Martyn, A.C.; Parsons, P.G.; Fairlie, D.P. Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. J. Med. Chem., 2004, 47, 2984-2994.
114. Kahnberg, P.; Lucke, A.J.; Glenn, M.P.; Boyle, G.M.; Tyndall, J.D.A.; Parsons, P.G.; Fairlie, D.P. design.; synthesis.; potency.; and cytoselectivity of anticancer agents derived by parallel synthesis from α-aminosuberic acid. J. Med. Chem., 2006, 49, 7611-7622.
115. Shen, J.; Woodward, R.; Kedenburg, J.P.; Liu, X.; Chen, M.; Fang, L.; Sun, D.; Wang, P.G. Histone Deacetylase Inhibitors through Click Chemistry. J. Med. Chem., 2008, 51, 7417-7427.
116. Zhang, Y.; Fang, H.; Jiao, J.; Xu, W. The Structure and Function of Histone Deacetylases.; The Target for Anti-cancer Therapy. Curr. Med. Chem., 2008, 15, 2840-2849.
117. Wang, H.; Yu, N.; Chen, D.; Lee, K.C.L.; Lye, P.L.; Chang, J.W.W.; Deng, W.; Ng, M.C.Y.; Lu, T.; Khoo, M.L.; Poulsen, A.; Sangthongpitag, K.; Wu, X.; Hu, C.; Goh, K.C.; Wang, X.; Fang, L.; Goh, K.L.; Khng, H.H.; Goh, S.K.; Yeo, P.; Liu, X.; Bonday, Z.; Wood, J.M.; Dymock, B.W.; Ethirajulu, K.; Sun, E.T. Discovery of (2E)-3-{2-Butyl-1-2-(diethylamino)ethyl.-1Hbenzimidazol-5-yl}-N- hydroxyacrylamide (SB939.;an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile. J. Med. Chem., 2011, 54, 4694-4720.
118. Varghese, S.; Gupta, D.; Baran, T.; Jiemjit, A.; Gore, S.D.; Casero, R.A.; Woster, P.M. Alkyl-substituted polyaminohydroxamic acids.; a novel class of targeted histone deacetylase inhibitors. J. Med. Chem., 2005, 48, 6350-6365.
119. Gediya, L.K.; Chopra, P.; Purushottamachar, P.; Maheshwari, N.; Njar, C.O. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J. Med. Chem., 2005, 48, 5047-5051.
120. Inks, E.S.; Josey, B.J.; Jesinkey, S.R.; Chou, C.J. A novel class of small molecule inhibitors of HDAC6. ACS Chem. Biol., 2012, 17, 331-339.
121. Guan, P.; Sun, F.; Hou, X.; Wang, F.; Yi, F.; Xu, W.; Fang, H. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors. Bioorg. Med. Chem., 2012, 20, 3865-3872.
122. Blanquart, C.; Francois, M.; Charrier, C.; Bertrand, P.; Gregoire, M. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds. Curr. Cancer Drug Targets, 2011, 11, 919-928.
123. Rodriqueza, M.; Aquinoa, M.; Brunoa, I.; Martinoa, G.D.; Taddeib, M.; Gomez-Paloma, L. Chemistry and biology of chromatin remodeling agents.; state of art and future perspectives of HDAC inhibitors. Curr. Med. Chem., 2006, 13, 1119-1139.
124. Suzuki, T.; Nagano, Y.; Kouketsu, A.; Matsuura, A.; Maruyama, S.; Kurotaki, M.; Nakagawa, H.; Miyata, N. Novel inhibitors of human histone deacetylases.; design.; synthesis.; enzyme inhibition.; and cancer cell growth inhibition of SAHA-based nonhydroxamates. J. Med. Chem., 2005, 48, 1019-1032.